Adam Gehring
Board Member
Toronto, Canada
Adam Gehring received his Ph.D. at Case Western Reserve University in Cleveland, Ohio. His training included a Postdoctoral Fellowship in the Institute of Hepatology at University College London and a position of Senior Research Fellow, and subsequently Assistant Principal Investigator, at the Singapore Institute for Clinical Sciences with Antonio Bertoletti. During his postdoctoral training Dr. Gehring was instrumental in developing TCR gene therapy for chronic HBV. His foundational work resulted in human application of engineered T cells for HBV-related HCC tumors expressing viral antigen. Dr. Gehring moved to Saint Louis University as an Assistant Professor in the Molecular Microbiology and Immunology department in March 2013 before joining the Toronto Center for Liver Disease as Biology Lead in February 2016.
Dr. Gehring is currently Co-Chair for the Immune Monitoring Workgroup of the HBV Forum. He is Co-Chair for the International HBV Meeting being organized in Toronto in September, 2021.
Dr. Gehring runs a translational HBV immunology research lab focused on liver pathogenesis and sex-based differences in disease progression. His primary interest lies in defining the mechanisms driving liver inflammation during HBV-related flares using functional and transcriptomic approaches in liver biopsies. He has established an internal immune monitoring core within his lab to process and analyze immune responses in Phase 2 clinical studies for HBV.